ライフサイエンスコーパス: metastatic disease

1 ent, and 18 with neuroblastoma without brain metastatic disease).

2 up to two previous lines of chemotherapy for metastatic disease.

3 rimary tumours, ~50% of patients progress to metastatic disease.

4 on of primary tumors and are ineffective for metastatic disease.

5 herapeutic agents that are effective against metastatic disease.

6 formation about the major characteristics of metastatic disease.

7 omarker-directed therapies for patients with metastatic disease.

8 in embryonic development, tissue repair, and metastatic disease.

9 to identify a distant primary malignancy or metastatic disease.

10 d in colorectal adenocarcinoma patients with metastatic disease.

11 in ~70-80% of patients with early-stage, non-metastatic disease.

12 enograft models, particularly in relation to metastatic disease.

13 recurrence of kidney cancer and of dying of metastatic disease.

14 e challenges associated with treating (micro)metastatic disease.

15 ing 30-40% of patients relapse with terminal metastatic disease.

16 tive therapeutic target for the treatment of metastatic disease.

17 erall survival for patients with advanced or metastatic disease.

18 r bulk, and is potentially down-regulated in metastatic disease.

19 Most cancer patients die of metastatic disease.

20 uring mouse development and is implicated in metastatic disease.

21 r melanoma-related death in both primary and metastatic disease.

22 e tissue samples, including both primary and metastatic disease.

23 etion of first-line/initial chemotherapy for metastatic disease.

24 nonmetastatic disease and 0.31 in those with metastatic disease.

25 cted survival of neuroblastoma patients with metastatic disease.

26 with the liver being the most common site of metastatic disease.

27 of alterations associated with recurrent and metastatic disease.

28 nd more than 50% of patients presenting with metastatic disease.

29 ating intrahepatic HCC even in patients with metastatic disease.

30 lular transformation, disease progression to metastatic disease.

31 n cancer types with no effective therapy for metastatic disease.

32 cer-related deaths, primarily due to distant metastatic disease.

33 eria in Solid Tumors (RECIST) for measurable metastatic disease.

34 tial for the development of solid tumors and metastatic disease.

35 is sculpted differentially by primary versus metastatic disease.

36 0 years and eventually progress to incurable metastatic disease.

37 y correlated positively with the presence of metastatic disease.

38 dow associates with high risk for subsequent metastatic disease.

39 ere compared with patients with disseminated metastatic disease.

40 or prevents progression of both primary and metastatic disease.

41 ived chemotherapy for unresectable recurrent/metastatic disease.

42 ns, especially in the context of surgery and metastatic disease.

43 remain at risk for local recurrences and/or metastatic disease.

44 optotic elimination of advanced invasive and metastatic disease.

45 ally significant PCa and with progression to metastatic disease.

46 nd GSS in AYA patients, including those with metastatic disease.

47 eatment approach exists for the treatment of metastatic disease.

48 rathoracic lymph nodes only) or disseminated metastatic disease.

49 th lung cancer, particularly in advanced and metastatic disease.

50 biomarker of disease progression and perhaps metastatic disease.

51 avenous contrast demonstrated no evidence of metastatic disease.

52 ard treatment for patients with advanced and metastatic disease.

53 atient developed externalization of tumor or metastatic disease.

54 dearth of effective therapeutic options for metastatic disease.

55 ortality and morbidity reported for advanced metastatic disease.

56 ent demonstrated externalization of tumor or metastatic disease.

57 rine resistance especially in the setting of metastatic disease.

58 esent a therapeutic opportunity for managing metastatic disease.

59 Staging scans were negative for metastatic disease.

60 nonmetastatic disease and 0.61 in those with metastatic disease.

61 o localized prostate cancer and subsequently metastatic disease.

62 h solid malignancy, only 51 (17 %) had known metastatic disease.

63 efits of this drug in patients with advanced metastatic disease.

64 umor phenotype in vivo and mirror late stage metastatic disease.

65 alized treatment strategies in patients with metastatic disease.

66 apeutic target to prevent the development of metastatic disease.

67 esent with localised or locally advanced non-metastatic disease.

68 strategies aimed at preventing and treating metastatic disease.

69 , and greatly extended survival of mice with metastatic disease.

70 t may change clinical approaches to managing metastatic disease.

71 of alterations associated with recurrent and metastatic disease.

72 lished tumors and a significant reduction in metastatic disease.

73 ervention in the prevention and treatment of metastatic disease.

74 tastatic disease and 3 patients with osseous metastatic disease.

75 rapies leads to systemic tumor recurrence of metastatic disease.

76 r breast cancer patients with drug-resistant metastatic disease.

77 different anatomical sites usually represent metastatic disease.

78 Nearly all breast cancer deaths result from metastatic disease.

79 ble prognostic estimates among patients with metastatic disease.

80 ple-negative breast cancer (TNBC) and drives metastatic disease.

81 o endocrine treatments (ET) and relapse with metastatic disease.

82 ve treatment for breast cancer patients with metastatic disease.

83 tal chains (Figs 1A and 1C), without distant metastatic disease.

84 es or as first-line options for recurrent or metastatic disease.

85 es remain poor for patients with relapsed or metastatic disease.

86 f invasive cancer in the remnant pancreas or metastatic disease.

87 highlighting new avenues for therapy against metastatic disease.

88 DNMT3B induction as new option for treating metastatic disease.

89 tients are diagnosed at an advanced stage of metastatic disease.

90 er development, from dysplasia to full-blown metastatic disease.

91 sions to carcinoma in situ and eventually to metastatic disease.

92 t worse compared with those who have de-novo metastatic disease.

93 ncer-related deaths for women, due mainly to metastatic disease.

94 hs annually, attributed largely to incurable metastatic disease.

95 esion, enabling confirmation of subcutaneous metastatic disease.

96 , de-differentiation, cancer progression and metastatic disease.

97 n profile that differentiates localized from metastatic disease.

98 semination and the probability of developing metastatic disease.

99 potential target in the management of liver metastatic disease.

100 ant metastatic site(s) before becoming overt metastatic diseases.

101 and lead to novel therapeutic strategies for metastatic diseases.

102 provides an attractive approach for treating metastatic diseases.

103 imens for unresectable, locally advanced, or metastatic disease (0 or 1 vs >1), and disease involveme

104 The liver is the most common site of metastatic disease(1).

105 with LGT tumors, including 15 patients with metastatic disease, 1 patient with suspected local relap

106 rd systemic therapy (69% M1a; 43% M1b/c) for metastatic disease (153/382, 40%).

107 A total of 52% of the patients had metastatic disease, 20% had node-positive or node-indete

108 milar to those of unenhanced PET/CT (distant metastatic disease: 28 of 29 [96%] for readers 3 and 4,

109 eived two or more prior lines of therapy for metastatic disease, 82% were PD-L1 positive, and 22% wer

110 55% men in arms B and D, respectively), and metastatic disease (88% and 84% in arms B and D, respect

111 urate local staging and earlier detection of metastatic disease, accurate identification of oligometa

112 as significantly increased for patients with metastatic disease (adjusted hazard ratio [AHR], 2.3; 95

113 in which authors described the resolution of metastatic disease after irradiation of a single lesion

114 lopment, local tumor recurrence, presence of metastatic disease after surgery, and sufficiency of the

115 included in this analysis, of whom 20 had no metastatic disease and 20 had metastasis.

116 48 samples across 3 patients with lymph node metastatic disease and 3 patients with osseous metastati

117 neity in subclonal structure from primary to metastatic disease and between metastatic sites, such th

118 Patients with cancer with metastatic disease and cancer survival outcomes related

119 hildren, frequently presents with aggressive metastatic disease and for these children the 5-year sur

120 lso been implicated in tumor progression and metastatic disease and have thus become an attractive th

121 Given the high incidence of metastatic disease and poor long-term prognosis of ASPS,

122 tients correlates with faster progression to metastatic disease and poor prognosis.

123 of patients with local, locally advanced, or metastatic disease and predict their respective survival

124 eved breakthroughs for treating recurrent or metastatic disease and represent a promising future dire

125 ctional imaging confirmed widespread osseous metastatic disease and right supraclavicular lymph node

126 in melanoma and this is associated with less metastatic disease and stronger host immune responses.

127 ssessment of SYK activity as a biomarker for metastatic disease and the use of fostamatinib as a mean

128 an lung is developed to study the biology of metastatic disease and therapeutic intervention.

129 ET/CT enables discrimination of local versus metastatic disease and thus might have a crucial impact

130 up performance status of 0 or 1, progressive metastatic disease, and adequate haematological, renal,

131 onary resuscitation, previous ICU admission, metastatic disease, and admission for respiratory reason

132 tors: PRETEXT I/II, PRETEXT III, PRETEXT IV, metastatic disease, and AFP concentration of 100 ng/mL o

133 , involvement of multiple body compartments, metastatic disease, and bone marrow infiltration.

134 emotherapy or biological treatment for their metastatic disease, and had an Eastern Cooperative Oncol

135 east cancer development and the promotion of metastatic disease, and its expression in breast tumors

136 ould prove useful in determining the risk of metastatic disease, and its manipulation might offer a n

137 stem cell properties are key contributors to metastatic disease, and there remains a need to better u

138 Patients who present with metastatic disease are consigned to stage 4, and the TNM

139 e OMM metastasis, and systemic therapies for metastatic disease are largely palliative.

140 ng increasingly common because patients with metastatic disease are living longer.

141 vers of invasive progression, high-grade and metastatic disease are poorly defined.

142 Most patients with metastatic disease are treated with systemic agents, whi

143 sed late, when already a locally advanced or metastatic disease, as there are no useful biomarkers fo

144 vements in clinical and molecular staging of metastatic disease, as well as integration of effective

145 Kaplan-Meier estimate for absence of metastatic disease at 5 years was 78.5% (95% CI, 54.77%-

146 ease at diagnosis; 38 of 103 (37%) developed metastatic disease at a median of 5.9 months (interquart

147 ely to have Gleason scores >/= 8 ( P = .05), metastatic disease at diagnosis ( P = .01), higher PSA (

148 d with overall survival were the presence of metastatic disease at diagnosis, and whether the chest t

149 ification on the basis of the burden of lung metastatic disease at diagnosis.

150 Seventeen of 103 (16%) patients had metastatic disease at diagnosis; 38 of 103 (37%) develop

151 r Hispanic ethnicity increased the chance of metastatic disease at presentation when controlling for

152 reader 1, seven of eight [88%] for reader 2) metastatic disease at rates similar to those of unenhanc

153 ab with no evidence of disease recurrence or metastatic disease at study entry.

154 f circulating melanoma cells and reduced the metastatic disease burden in patient-derived xenografts

155 ion free survival, suggesting a reduction in metastatic disease burden.

156 ts who experience relapse after treatment of metastatic disease but worse compared with those who hav

157 ike bladder cancer (BC) subtype tend to have metastatic disease, but this is unconfirmed.

158 by 14/23 (61%) and a systemic screening of a metastatic disease by 13/23 (57%).

159 therapeutic approaches to prevent or target metastatic disease by harnessing NK cells.

160 cascade and the establishment of aggressive, metastatic disease by reactivating a latent embryonic pr

161 Isolating those LNs most likely to harbor metastatic disease can allow for a more rigorous evaluat

162 wever, disease recurrence and development of metastatic disease can occur despite appropriate treatme

163 ents had received prior systemic therapy for metastatic disease (cervical, 78.9%; vaginal/vulvar, 80.

164 We generated xenograft models of HTR metastatic disease characterized by EVs in the periphera

165 For metastatic disease, chemotherapy as initial treatment no

166 For patients with advanced-stage or metastatic disease, comprehensive genomic profiling has

167 ence of any of the risk factors and no known metastatic disease, controls).

168 ccessful sentinel-lymph-node mapping who had metastatic disease correctly identified in the sentinel

169 Early detection of recurrent or metastatic disease could improve patient prognosis by tr

170 patients, and especially those with advanced metastatic disease, deep sequencing of circulating cell

171 Twenty-one patients developed metastatic disease detected by surveillance and confirme

172 re difference in per-patient specificity for metastatic disease detection between standard and WB-MRI

173 re difference in per-patient specificity for metastatic disease detection between standard and WB-MRI

174 cell carcinoma who received cabozantinib for metastatic disease during any treatment line roughly bet

175 Among the patients who developed metastatic disease during neoadjuvant treatment, median

176 unresectable, locally advanced, recurrent or metastatic disease, Eastern Cooperative Oncology Group p

177 Survival is worse with preoperative metastatic disease, especially osteosarcoma.

178 tantly, microvesicles from patients with HTR metastatic disease expressed high levels of miR-221.

179 ERalpha breast cancer patients relapse with metastatic disease following adjuvant endocrine therapie

180 The remaining 21 cases showed no signs of metastatic disease for an average follow-up of 10 years.

181 ard of complete lymphadenectomy in detecting metastatic disease for endometrial cancer.

182 squamous cell carcinoma of the anus without metastatic disease from 59 centres in the UK.

183 atients receiving 2 L treatment for advanced/metastatic disease from January 2013 to July 2015.

184 ether it genuinely arises at the ovary or is metastatic disease from other organs.

185 Patients with metastatic disease had OS rates of 77.8% and 22.2% at 1-

186 Acute liver failure (ALF) induced by diffuse metastatic disease has rarely been reported.

187 However, patients with recurrent or metastatic disease have 5-year survival rates of less th

188 drive the progression of primary melanoma to metastatic disease have been studied extensively, the ea

189 ogrammed regulatory elements commissioned in metastatic disease hijack latent developmental programs,

190 e during progression from in situ lesions to metastatic disease; however, the metastasis-associated s

191 finitive local treatments, and with advanced metastatic disease in 13 of 18 (72%), 8 of 12 (67%), and

192 locoregional lymph nodes in 39%, and distant metastatic disease in 16%.

193 uclear BAP1 had decreased odds of developing metastatic disease in a multivariate model (P = 0.042).

194 The emergence of metastatic disease in cancer patients many years or deca

195 of MDM2-ALT1 has been observed in aggressive metastatic disease in pediatric rhabdomyosarcoma (RMS),

196 Six patients showed metastatic disease in the central nervous system.

197 ational study was conducted in patients with metastatic disease in the lower limb.

198 he only significant independent predictor of metastatic disease in this study.

199 that a drug repurposing approach to prevent metastatic disease in TNBC exploits lipid anabolism as a

200 was alive with metastases, and 6 had died of metastatic disease (including 2 patients who declined ad

201 In metastatic disease, increased percentage of tumors with

202 nnovative preclinical model systems to study metastatic disease; increased sharing of resources and d

203 Progression to metastatic disease is a leading cause of cancer death.

204 Current understanding of metastatic disease is limited due to difficulty of sampl

205 e suggesting that the effect of P-AscH(-) on metastatic disease is mediated by hydrogen peroxide.

206 the deadliest malignancies as advanced stage metastatic disease is mostly untreatable, thus warrants

207 oth HPV+ and HPV- subtypes with recurrent or metastatic disease is poor.

208 Metastatic disease is the leading cause of cancer-relate

209 Adrenalectomy for metastatic disease is well-described, although indicatio

210 ocal treatment (LT), even in the presence of metastatic disease, is beneficial.

211 ccurring metastases-that is, treatment-naive metastatic disease-is largely unknown.

212 During treatment of metastatic disease, it is useful to predict response and

213 tudies in patients with advanced, inoperable metastatic disease, its use in the perioperative setting

214 fluoride (NaF PET) for assessment of osseous metastatic disease led to changes in intended management

215 rapy, extensive surgery for locoregional and metastatic disease, local ablative therapies for metasta

216 ognosis with localized, locally advanced, or metastatic disease (log-rank test, P < 0.001), whereas C

217 00 ng/mL; and the PRETEXT annotation factors metastatic disease (M), macrovascular involvement of all

218 ocalization (n = 225/388, 58%), or restaging metastatic disease (M1) before or during systemic therap

219 Recognition of microscopic metastatic disease may prove beneficial in staging and g

220 A. and approximately 50% of patients develop metastatic disease (mCRC).

221 ves as a tunable site to molecularly dissect metastatic disease mechanisms.

222 prised patients restaged with known advanced metastatic disease (n = 103), after androgen deprivation

223 chondrosarcoma; for locally advanced and/or metastatic disease, no known effective systemic therapy

224 ab, there were no CT findings that suggested metastatic disease, nor were there enlarged mediastinal

225 lity in patients with UrC-ADC by identifying metastatic disease not appreciated on anatomic imaging,

226 ent risk factors for hospital mortality were metastatic disease (odds ratio, 1.99), cardiopulmonary r

227 iagnosed colon cancer were not known to have metastatic disease of their primary tumor.

228 Pelvic nodal and extrapelvic metastatic disease on (68)Ga-PSMA-11 PET/CT (PSMA T0N1M0

229 evaluated, 16 of which demonstrated local or metastatic disease on (68)Ga-PSMA-HBED-CC PET/CT.

230 evaluated, 16 of whom demonstrated local or metastatic disease on (68)Ga-PSMA-HBED-CC PET/CT.

231 isoforms is a promising approach to address metastatic disease, one that may be readily combined wit

232 On subset analysis of 91 AYA patients with metastatic disease, operative management was associated

233 adiol have focused on diagnosing ER-positive metastatic disease, optimizing ER-targeted drug dosage,

234 No patients demonstrated endophthalmitis or metastatic disease or died during the study window.

235 Metastatic disease or family history suggestive of hered

236 gical complications directly attributable to metastatic disease or other concurrent cancer-related tr

237 The patients with aggressive metastatic disease or refractory/relapsed neuroblastoma

238 atinum-containing treatment for recurrent or metastatic disease (or both), or whose disease recurred

239 , intermediate, high, nodal involvement, and metastatic disease) or oncologic management changes were

240 ere better at predicting overall survival in metastatic disease (OSmet) when analyzed in metastatic t

241 = 0.014), nodal involvement (p = 0.019) and metastatic disease (p = 0.008).

242 has not been studied in the context of bone metastatic disease previously.

243 (defined as not receiving ADT at the time of metastatic disease progression) aged 18 years and older,

244 lly initiate neuroblastoma and contribute to metastatic disease progression.

245 found for Gleason grade, stage, presence of metastatic disease, PSA velocity, or PSA doubling time.

246 nts with nonmetastatic CRPC at high risk for metastatic disease (rapid prostate-specific antigen doub

247 Furthermore, the subcutaneous metastatic disease remained stable during the treatment

248 hose with stage IV cancer, 23.5% of men with metastatic disease reported no problems on any EQ-5D dim

249 (87%) of patients with locally advanced and metastatic disease, respectively.

250 ion and thus the establishment of aggressive metastatic disease.See related article by Shinde et al.,

251 for patients at highest risk for developing metastatic disease.See related commentary by Ingman, p.

252 %), nodal involvement (one of 79, 1.3%), and metastatic disease (seven of 79, 8.9%).

253 [96%] for readers 3 and 4, P = .50; axillary metastatic disease: seven of eight [88%] for readers 3 a

254 Men with advanced or metastatic disease should be offered endocrine therapy a

255 and many patients with locally advanced and metastatic disease show increases in circulating SAA.

256 Preplanned subgroup analyses in men with metastatic disease showed a hazard ratio of 0.78 (95% CI

257 isk factors (p=0.0403) and higher numbers of metastatic disease sites (p=0.0414) were associated with

258 ted radiometals to deliver beta-radiation to metastatic disease sites, with (177)Lu being the most wi

259 rapeutic targets for cancers evolving into a metastatic disease state.

260 isk disease, newly diagnosed treatment-naive metastatic disease, suspected recurrent disease after lo

261 To reduce the risk of subsequent metastatic disease, systemic chemotherapy can be introdu

262 Deaths from cancer are mostly due to metastatic disease that becomes resistant to therapy.

263 cells had potent synergistic effects against metastatic disease that was already established in secon

264 Consequently, in metastatic disease, the utility of external-beam radioth

265 oved survival; however, local recurrence and metastatic disease-the principal causes of cancer mortal

266 For people presenting without metastatic disease, therapeutic goals are tumor eradicat

267 idence of cancer is increasing worldwide and metastatic disease, through the spread of circulating tu

268 subcompartment in primary tumors may prevent metastatic disease, thus representing an effective strat

269 ong entire cohort, 11.5% among patients with metastatic disease to any distant site) and triple-negat

270 ong entire cohort, 11.4% among patients with metastatic disease to any distant site) subtypes.

271 e entire cohort and 7.56% of the subset with metastatic disease to any site.

272 ts with histologically proven malignancy and metastatic disease to the central nervous system or lept

273 history of radiation therapy to the jaws or metastatic disease to the jaws.

274 Further, studies on resection for metastatic disease to the lung were systematically revie

275 Priority genes to test for metastatic disease treatment included BRCA2, BRCA1, and

276 o radiotherapy planned and for patients with metastatic disease, treatment continued until radiologic

277 Therefore, most patients with metastatic disease typically receive systemic agents, wh

278 primitive lung-in-a-dish (PLiD), to recreate metastatic disease using primary and established cancer

279 USBR for SB-NETs in the presence of metastatic disease was associated with better patient-or

280 fluoride (NaF PET) for assessment of osseous metastatic disease was associated with substantial chang

281 Loss of RD3 in metastatic disease was examined using a mouse model of P

282 g the treatment period, and no other site of metastatic disease was noted on follow-up CT scans obtai

283 ility to differentiate between localized and metastatic disease, was also determined.

284 ability to distinguish between localized and metastatic disease, was also noted.

285 f the sentinel-lymph-node-based detection of metastatic disease, was defined as the proportion of pat

286 highlighted when patients with more limited metastatic disease were compared with patients with diss

287 tive primary breast cancer and biopsy-proven metastatic disease were enrolled in a prospective clinic

288 cancer and no prior therapy for advanced or metastatic disease were randomized to letrozole with or

289 creases overall survival among patients with metastatic disease when it is added to trastuzumab and c

290 static tumor setting, or early vs late stage metastatic disease, when undergoing vector design.

291 hment of a cancer cell to the development of metastatic disease, which is dependent on immune evasion

292 rriers to progress is the necessary focus on metastatic disease, which is often challenging, expensiv

293 Almost 50% of patients develop metastatic disease, which usually involves the liver, an

294 therapy are at a high risk of recurrence for metastatic disease, which, in turn, make these patients

295 ociated with number of sites at the onset of metastatic disease, while high levels of MLR and NLR wer

296 To evaluate outcome in patients with limited metastatic disease who receive chemotherapy first and pr

297 Patients with limited metastatic disease who received neoadjuvant chemotherapy

298 Lung squamous carcinoma (LUSC) is a highly metastatic disease with a poor prognosis.

299 ting chemotherapy demonstrated an absence of metastatic disease with expected avidity in two separate

300 atients after diagnosis of colorectal cancer metastatic disease, yet how RAS-ERK signaling regulates